HURA · TuHURA Biosciences, Inc.

TuHURA Biosciences reported first quarter 2026 financial results reflecting ongoing investment in its immuno-oncology pipeline, with research and development expenses rising to $5.2 million from $4.6 million in the prior year quarter, driven by clinical development activities for IFx-2.0, TBS-2025, and MDSC inhibitors. General and administrative expenses increased modestly to $2.3 million from $2.0 million, indicating stable overhead amid leadership enhancements. Net cash outflows from operations improved slightly to $4.4 million from $4.7 million, supported by $7.2 million in financing inflows. Balance sheet shows $6.3 million in cash and equivalents at quarter-end with 63.6 million shares outstanding. A pivotal development is the April 2026 $50 million non-equity credit facility from the largest stockholder, bearing 12% interest on drawn amounts, payable monthly, with principal due in April 2031. This drawable facility extends cash runway into 2028, providing flexibility beyond anticipated Phase 3 topline data for IFx-2.0 in Merkel Cell Carcinoma. CEO Dr. James Bianco highlighted execution on strategy, including FDA meetings for TBS-2025 IND in mutant NPM1 relapsed/refractory AML, lead ADC selection, and Phase 3 enrollment completion. Leadership bolstering includes Craig Tendler, M.D., providing CMO-equivalent services and Amanda Garofalo as SVP Clinical Operations. FDA Orphan Drug Designation for IFx-2.0 in melanoma adds to MCC designation anticipated in 1H 2026. These updates signal pipeline advancement and funding security critical for investor confidence in this Phase 3-stage biotech.